Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

ROBERT A DICHMANN

Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology

NPI
1245232578
CMS profile
328270
Location
SANTA MARIA, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2021 · Entire year

$18.12

2 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2021 · entire year · sorted by reported total

Nature of paymentAmountRecords
Education $18.12 2

By paying entity

PY2021 · entire year · sorted by reported total

Paying entityAmountRecords
Merck Sharp & Dohme Corporation $18.12 2

Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

ROBERT A DICHMANN

NPI 1245232578 · CMS profile ID 328270

Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology

SANTA MARIA, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1245232578?year=2021&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
ROBERT A DICHMANN, NPI 1245232578, CMS profile ID 328270. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1245232578?year=2021&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
APA 7
IndustryPayments. (2026). ROBERT A DICHMANN, NPI 1245232578, CMS profile ID 328270. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1245232578?year=2021&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
Bluebook
ROBERT A DICHMANN, NPI 1245232578, CMS profile ID 328270, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1245232578?year=2021&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30

2 matching records · $18.12 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 2 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–2 of 2.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Merck Sharp & Dohme Corporation $7.2501/13/2021 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848307735 CMS
Merck Sharp & Dohme Corporation $10.8701/13/2021 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848313385 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $328.73 22
PY2020 $104.19 8
PY2021 $18.12 2
PY2022 $14.08 1
PY2023 $26.48 1

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023
Generated from
OP_DTL_GNRL_PGYR2023_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $5,981.45 2
PY2024 Principal investigator $7,185.45 2
PY2023 Principal investigator $33,549.76 11
PY2022 Principal investigator $162,021.03 21
PY2021 Principal investigator $97,528.06 21
PY2020 Principal investigator $227,117.30 35
PY2019 Principal investigator $393,411.87 53

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

21 records in PY2022

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 AstraZeneca UK Limited $18.73 12/31/2022 Covered Recipient Teaching Hospital
St. Josephs Hospital & Medical Ctr
A Phase III Double-blind Randomised Study Assessing the Efficacy and Safety of Capivasertib + Fulvestrant Versus Placebo + Fulvestrant as Treatment for Locally Advanced (Inoperable) or Metastatic Hormone Receptor Positive, Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2?) Breast Cancer Following Recurrence or Progression On or After Treatment with an Aromatase Inhibitor (CAPItello-291) No dispute reported 06/30/2026 914602329
Principal investigator 1 Merck Sharp & Dohme LLC $149.79 12/31/2022 Non-covered Recipient Entity
CENTRAL COAST MEDICAL ONCOLOGY CORPORATION
A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer with 1 cm Residual Invasive Cancer or Positive Lymph Nodes pN1mic After Neoadjuvant Chemotherapy No dispute reported 06/30/2026 940406423
Principal investigator 2 Celgene Corporation $7,285.00 09/13/2022 Covered Recipient Teaching Hospital
Sacred Heart Hospital
Connect MM- The Multiple Myeloma Disease Registry No dispute reported 06/30/2026 937183405
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $1,794.00 06/28/2022 Non-covered Recipient Entity
Translational Oncology Research International
Phase IIIB/IV Safety Trial of Nivolumab Combined with Ipilimumab in Subjects with Previous Untreated, Advanced or Metastatic RCC No dispute reported 06/30/2026 933198773
Principal investigator 1 Seagen Inc. $2,000.00 05/24/2022 Non-covered Recipient Entity
CENTRAL COAST MEDICAL ONCOLOGY
Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib No dispute reported 06/30/2026 917881531
Principal investigator 1 Seagen Inc. $2,000.00 05/24/2022 Non-covered Recipient Entity
CENTRAL COAST MEDICAL ONCOLOGY
Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib No dispute reported 06/30/2026 917881541
Principal investigator 1 Seagen Inc. $2,000.00 05/24/2022 Non-covered Recipient Entity
CENTRAL COAST MEDICAL ONCOLOGY
Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib No dispute reported 06/30/2026 917881547
Principal investigator 1 Novartis Pharmaceuticals Corporation $451.00 05/19/2022 Non-covered Recipient Entity
CENTRAL COAST MEDICAL ONCOLOGY
RIBOCICLIB STANDARD ENDOCRINE THERAPY IN PATIENTS WITH HR HER2 EARLY BC AT HIGH AMP INTERMEDIATE RISK FOR RECURRENCE No dispute reported 06/30/2026 909394591
Principal investigator 1 Novartis Pharmaceuticals Corporation $0.94 05/09/2022 Non-covered Recipient Entity
CENTRAL COAST MEDICAL ONCOLOGY
MONALEESA 3 A RANDOMIZED DOUBLE BLIND PLACEBOCONTROLLED STUDY OF RIBOCICLIB IN COMBINATION WITH FULVESTRANT FOR THE TREATMENT OF POSTMENOPAUSAL WOMEN WITH HORMONE RECEPTOR POSITIVE HER2 NEGATIVE ADVANCED BREAST CANCER WHO HAVE RECEIVED NO OR ONLY ONE LINE No dispute reported 06/30/2026 909394583
Principal investigator 1 Merck Sharp & Dohme LLC $2,500.00 05/04/2022 Non-covered Recipient Entity
CENTRAL COAST MEDICAL ONCOLOGY CORPORATION
A Randomized open-Label Phase III Trial of Pembrolizumab versus Platinum based Chemotherapy in 1L Subjects with PD-L1 Strong Metastatic Non-Small Cell Lung Cancer No dispute reported 06/30/2026 940403345
Principal investigator 1 Seagen Inc. $794.00 03/24/2022 Non-covered Recipient Entity
CENTRAL COAST MEDICAL ONCOLOGY
Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib No dispute reported 06/30/2026 917881535
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $794.00 03/22/2022 Non-covered Recipient Entity
Translational Oncology Research International
A Phase IIIb/IV Safety Trial of Nivolumab (BMS-936558) in Subjects with Advanced or Metastatic Renal Cell Carcinoma Who Have Progressed During or After Receiving One Prior Systemic Regimen No dispute reported 06/30/2026 933187119
Principal investigator 1 AstraZeneca UK Limited $17,750.00 03/21/2022 Covered Recipient Teaching Hospital
St. Josephs Hospital & Medical Ctr
A Phase III Double-blind Randomised Study Assessing the Efficacy and Safety of Capivasertib + Fulvestrant Versus Placebo + Fulvestrant as Treatment for Locally Advanced (Inoperable) or Metastatic Hormone Receptor Positive, Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2?) Breast Cancer Following Recurrence or Progression On or After Treatment with an Aromatase Inhibitor (CAPItello-291) No dispute reported 06/30/2026 914603651
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $8,483.00 03/17/2022 Non-covered Recipient Entity
Translational Oncology Research International
An Open Label Phase 2 Multicohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CheckMate 627) No dispute reported 06/30/2026 933187687
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $7,936.00 03/01/2022 Non-covered Recipient Entity
Translational Oncology Research International
A Phase IIIb/IV Safety Trial of Nivolumab (BMS-936558) in Subjects with Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Progressed During or After Receiving At Least One Prior Systemic Regimen No dispute reported 06/30/2026 933187063
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $2,984.00 02/18/2022 Non-covered Recipient Entity
Translational Oncology Research International
Phase IIB 1L NSCLC Flat Dose Nivo Combo Schedule Safety - Phase IIIB/IV Safety Trial of Flat Dose Nivolumab in Combination with Ipilimumab in Participants with with non-small cell lung cancer No dispute reported 06/30/2026 933191993
Principal investigator 1 Novartis Pharmaceuticals Corporation $2,336.57 02/02/2022 Non-covered Recipient Entity
CENTRAL COAST MEDICAL ONCOLOGY
RIBOCICLIB STANDARD ENDOCRINE THERAPY IN PATIENTS WITH HR HER2 EARLY BC AT HIGH AMP INTERMEDIATE RISK FOR RECURRENCE No dispute reported 06/30/2026 910070633
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $1,239.00 02/01/2022 Non-covered Recipient Entity
Translational Oncology Research International
Phase III 1L Metastatic RCC Nivo Ipi Cabo No dispute reported 06/30/2026 933193589
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $10,157.00 01/18/2022 Non-covered Recipient Entity
Translational Oncology Research International
A Dose Frequency Optimization, Phase IIIB/IV Trial of Nivolumab 240 mg Every 2 Weeks vs Nivolumab 480 mg Every 4 Weeks in Subjects with Advanced or Metastatic Non-small Cell Lung Cancer who Received Up to 12 Months of Nivolumab at 3 mg/kg or 240 mg Every 2 Weeks. No dispute reported 06/30/2026 933186123
Principal investigator 1 Novartis Pharmaceuticals Corporation $7,479.00 01/14/2022 Non-covered Recipient Entity
TRANSLATIONAL RESEARCH IN ONCOLOGY INC
MONALEESA 3 A RANDOMIZED DOUBLE BLIND PLACEBOCONTROLLED STUDY OF RIBOCICLIB IN COMBINATION WITH FULVESTRANT FOR THE TREATMENT OF POSTMENOPAUSAL WOMEN WITH HORMONE RECEPTOR POSITIVE HER2 NEGATIVE ADVANCED BREAST CANCER WHO HAVE RECEIVED NO OR ONLY ONE LINE No dispute reported 06/30/2026 909415143
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $83,869.00 01/13/2022 Non-covered Recipient Entity
Translational Oncology Research International
Phase III Multiple Myeloma 3L Combo nivo - elo - An Open-Label, Randomized Phase 3 Trial of Combinations of Nivolumab, Pomalidomide and Dexamethasone in Relapsed and Refractory Multiple Myeloma (CheckMate 602: CHECKpoint pathway and nivoluMAb clinical Tri No dispute reported 06/30/2026 933195273